Abstrakt

MikroRNA (miRNA) są małymi cząsteczkami kwasu rybonukleinowego, które mimo że nie podlegają procesowi translacji, pełnią ważną funkcję regulacyjną w komórkach eukariotycznych. Ich fizjologiczną funkcją jest utrzymywanie homeostazy komórek. Zaburzona ekspresja miRNA może spowodować rozwój wielu chorób, w tym chorób nowotworowych. Działanie miRNA polega na hamowaniu tworzenia się białek, w tym białek o właściwościach onkogennych i antyonkogennych. Mutacje w miejscach kodowania miRNA mogą prowadzić do nadmiernego lub zmniejszonego wytwarzania wspomnianych białek. Odkrycie miRNA i poznanie ich roli w komórce otworzyło nowe możliwości dla diagnostyki chorób nowotworowych. Zmiany poziomu odpowiednich miRNA, w krwiobiegu lub innych płynach ustrojowych, mogą być markerem diagnostycznym chorób. Diagnostyka onkologiczna mogłaby przebiegać na podstawie badań profilu miRNA pacjenta i porównania go z opracowanymi wcześniej profilami zmian miRNA powiązanymi z występowaniem danego rodzaju choroby nowotworowej. Informacja o zmianach profilu miRNA podstawowych w regulacji ekspresji genów związanych z procesami nowotworzenia, mogłaby się przyczynić do opracowania terapii eksperymentalnych opartych na przywróceniu pierwotnego poziomu miRNA w komórkach, a tym samym, na przywróceniu prawidłowej regulacji ekspresji genów. Coraz nowsze metody wyciszania i włączania ekspresji miRNA mogą w przyszłości zaowocować skutecznymi rozwiązaniami terapeutycznymi.

Przypisy

• 1. Amr K.S., Ezzat W.M., Elhosary Y.A., Hegazy A.E., Fahim H.H.,Kamel R.R.: The potential role of miRNAs 21 and 199-a in early diagnosisof hepatocellular carcinoma. Gene, 2016; 575: 66–70
  Google Scholar
• 2. Anfossi S., Giordano A., Gao H., Cohen E.N., Tin S., Wu Q., GarzaR.J., Debeb B.G., Alvarez R.H., Valero V., Hortobagyi G.N., Calin G.A.,Ueno N.T., Woodward W.A., Reuben J.M.: High serum miR-19a levelsare associated with inflammatory breast cancer and are predictiveof favorable clinical outcome in patients with metastatic HER2+ inflammatorybreast cancer. PLoS One, 2014; 9: e83113
  Google Scholar
• 3. Antolin S., Calvo L., Blanco-Calvo M., Santiago M.P., Lorenzo-Patiño M.J., Haz-Conde M., Santamarina I., Figueroa A., Antón-AparicioL.M., Valladares-Ayerbes M.: Circulating miR-200c and miR-141and outcomes in patients with breast cancer. BMC Cancer, 2015;15: 297
  Google Scholar
• 4. Asaga S., Kuo C., Nguyen T., Terpenning M., Giuliano A.E., HoonD.S.: Direct serum assay for microRNA-21 concentrations in earlyand advanced breast cancer. Clin. Chem., 2011; 57: 84–91
  Google Scholar
• 5. Basati G., Emami Razavi A., Abdi S., Mirzaei A.: Elevated level ofmicroRNA-21 in the serum of patients with colorectal cancer. Med.Oncol., 2014; 31: 205
  Google Scholar
• 6. Basati G., Razavi A.E., Pakzad I., Malayeri F.A.: Circulating levels ofthe miRNAs, miR-194, and miR-29b, as clinically useful biomarkersfor colorectal cancer. Tumour Biol., 2016; 37: 1781–1788
  Google Scholar
• 7. Beckett E.L., Martin C., Choi J.H., King K., Niblett S., Boyd L., DuesingK., Yates Z., Veysey M., Lucock M.: Folate status, folate-relatedgenes and serum miR-21 expression: Implications for miR-21 as abiomarker. BBA Clin., 2015; 4: 45–51
  Google Scholar
• 8. Branch A.D., Rice C.M.: Antisense gets a grip on miR-122 in chimpanzees.Sci. Transl. Med., 2010; 2: 13ps1
  Google Scholar
• 9. Cazzoli R., Buttitta F., Di Nicola M., Malatesta S., Marchetti A.,Rom W.N., Pass H.I.: microRNAs derived from circulating exosomesas noninvasive biomarkers for screening and diagnosing lung cancer.J. Thorac. Oncol., 2013; 8: 1156–1162
  Google Scholar
• 10. Chen L., Heikkinen L., Wang C., Yang Y., Sun H., Wong G.: Trendsin the development of miRNA bioinformatics tools. Brief. Bioinform.,2019; 20: 1836–1852
  Google Scholar
• 11. Chen W.Y., Zhao X.J., Yu Z.F., Hu F.L., Liu Y.P., Cui B.B., DongX.S., Zhao Y.S.: The potential of plasma miRNAs for diagnosis andrisk estimation of colorectal cancer. Int. J. Clin. Exp. Pathol., 2015;8: 7092–7101
  Google Scholar
• 12. Chen Y., Du M., Wang J., Xing P., Zhang Y., Li F., Lu X.: MiRNA-200a expression is inverse correlation with hepatocyte growth factorexpression in stromal fibroblasts and its high expression predicts agood prognosis in patients with non-small cell lung cancer. Oncotarget,2016; 7: 48432–48442
  Google Scholar
• 13. Conev N.V., Donev I.S., Konsoulova-Kirova A.A., ChervenkovT.G., Kashlov J.K., Ivanov K.D.: Serum expression levels of miR-17,miR-21, and miR-92 as potential biomarkers for recurrence afteradjuvant chemotherapy in colon cancer patients. BioSci. Trends,2015; 9: 393–401
  Google Scholar
• 14. Cui E.H., Li H.J., Hua F., Wang B., Mao W., Feng X.R., Li J.Y., WangX.: Serum microRNA 125b as a diagnostic or prognostic biomarker foradvanced NSCLC patients receiving cisplatin-based chemotherapy.Acta Pharmacol. Sin., 2013; 34: 309–313
  Google Scholar
• 15. Del Vescovo V., Grasso M., Barbareschi M., Denti M.A.: MicroRNAsas lung cancer biomarkers. World J. Clin. Oncol., 2014; 54: 604–620
  Google Scholar
• 16. Dou H., Wang Y., Su G., Zhao S.: Decreased plasma let-7c andmiR-152 as noninvasive biomarker for non-small-cell lung cancer.Int. J. Clin. Exp. Med., 2015; 8: 9291–9298
  Google Scholar
• 17. Ebrahimi A., Sadroddiny E.: MicroRNAs in lung diseases: Recentfindings and their pathophysiological implications. Pulm. Pharmacol.Ther., 2015; 34: 55–63
  Google Scholar
• 18. Eichelser C., Flesch-Janys D., Chang-Claude J., Pantel K.,Schwarzenbach H.: Deregulated serum concentrations of circulatingcell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 inhuman breast cancer development and progression. Clin. Chem.,2013; 59: 1489–1496
  Google Scholar
• 19. Erbes T., Hirschfeld M., Rücker G., Jaeger M., Boas J., Iborra S.,Mayer S., Gitsch G., Stickeler E.: Feasibility of urinary microRNA detectionin breast cancer patients and its potential as an innovativenon-invasive biomarker. BMC Cancer, 2015; 15: 193
  Google Scholar
• 20. Eyking A., Reis H., Frank M., Gerken G., Schmid K.W., Cario E.:MiR-205 and MiR-373 are associated with aggressive human mucinouscolorectal cancer. PLoS One, 2016; 11: e0156871
  Google Scholar
• 21. Feng C., Xian Q., Liu S.: Micro RNA-518 inhibits gastric cancercell growth by inducing apoptosis via targeting MDM2. Biomed.Pharmacother., 2018; 97: 1595-1602
  Google Scholar
• 22. Ferro A., Peleteiro B., Malvezzi M., Bosetti C., Bertuccio P., Levi F.,Negri E., La Vecchia C., Lunet N.: Worldwide trends in gastric cancermortality (1980–2011), with predictions to 2015, and incidence bysubtype. Eur. J. Cancer, 2014; 50: 1330–1344
  Google Scholar
• 23. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., MelloC.C.: Potent and specific genetic interference by double-strandedRNA in Caenorhabditis elegans. Nature, 1998; 391: 806–811
  Google Scholar
• 24. Gao F., Chang J., Wang H., Zhang G.: Potential diagnostic valueof miR-155 in serum from lung adenocarcinoma patients. Oncol.Rep., 2014; 31: 351–357
  Google Scholar
• 25. Ge W., Yu D.C., Li Q.G., Chen X., Zhang C.Y., Ding Y.T.: Expressionof serum miR-16, let-7f, and miR-21 in patients with hepatocellularcarcinoma and their clinical significances. Clin. Lab., 2014;60: 427–434
  Google Scholar
• 26. Geng Q., Fan T., Zhang B., Wang W., Xu Y., Hu H.: Five microRNAsin plasma as novel biomarkers for screening of early-stage non-smallcell lung cancer. Respir. Res., 2014; 15: 149
  Google Scholar
• 27. Ghanbari R., Mosakhani N., Sarhadi V.K., Armengol G., NouraeeN., Mohammadkhani A., Khorrami S., Arefian E., Paryan M., MalekzadehR., Knuutila S.: Simultaneous underexpression of let-7a-5p andlet-7f-5p microRNAs in plasma and stool samples from early stagecolorectal carcinoma. Biomark. Cancer, 2015; 7: 39–48
  Google Scholar
• 28. Hale M.D., Hayden J.D., Grabsch H.I.: Tumour-microenvironmentinteractions: Role of tumour stroma and proteins produced by cancerassociatedfibroblasts in chemotherapy response. Cell Oncol., 2013;36: 95–112
  Google Scholar
• 29. Hanahan D., Weinberg R.A.: Hallmarks of cancer: The next generation,Cell, 2011; 144: 646–674
  Google Scholar
• 30. Haseeb A., Makki M.S., Khan N.M., Ahmad I., Haqqi T.M.: Deepsequencing and analyses of miRNAs, isomiRs and miRNA inducedsilencing complex (miRISC)-associated miRNome in primary humanchondrocytes. Sci. Rep., 2017; 7: 15178
  Google Scholar
• 31. Hayes C.N., Chayama K.: MicroRNAs as biomarkers for liver diseaseand hepatocellular carcinoma. Int. J. Mol. Sci., 2016; 17: 280
  Google Scholar
• 32. Heegaard N.H., Schetter A.J., Welsh J.A., Yoneda M., Bowman E.D.,Harris C.C.: Circulating micro-RNA expression profiles in early stagenonsmall cell lung cancer. Int. J. Cancer, 2012; 130: 1378–1386
  Google Scholar
• 33. Higuchi T., Todaka H., Sugiyama Y., Ono M., Tamaki N., HatanoE., Takezaki Y., Hanazaki K., Miwa T., Lai S., Morisawa K., Tsuda M.,Taniguchi T., Sakamoto S.: Suppression of microRNA-7 (miR-7) biogenesisby nuclear factor 90-nuclear factor 45 complex (NF90-NF45)controls cell proliferation in hepatocellular carcinoma. J. Biol. Chem.,2016; 291: 21074–21084
  Google Scholar
• 34. Hu Z., Chen X., Zhao Y., Tian T., Jin G., Shu Y., Chen Y., Xu L., ZenK., Zhang C., Shen H.: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival ofnon-small-cell lung cancer. J. Clin. Oncol., 2010; 28: 1721–1726
  Google Scholar
• 35. Hu Z., Dong J., Wang L.E., Ma H., Liu J., Zhao Y., Tang J., Chen X.,Dai J., Wei Q., Zhang C., Shen H.: Serum microRNA profiling and breastcancer risk: The use of miR-484/191 as endogenous controls. Carcinogenesis,2012; 33: 828–834
  Google Scholar
• 36. Huang J., Wu J., Li Y., Li X., Yang T., Yang Q., Jiang Y.: Deregulationof serum microRNA expression is associated with cigarette smokingand lung cancer. Biomed. Res. Int., 2014; 2014: 364316
  Google Scholar
• 37. Huang Z., Huang D., Ni S., Peng Z., Sheng W., Du X.: Plasma micro-RNAs are promising novel biomarkers for early detection of colorectalcancer. Int. J. Cancer, 2010; 127: 118–126
  Google Scholar
• 38. Janevska D., Chaloska-Ivanova V., Janevski V.: Hepatocellular carcinoma:Risk factors, diagnosis and treatment. Open Access Maced. J.Med. Sci., 2015; 3: 732–736
  Google Scholar
• 39. Jiang L., Li X., Cheng Q., Zhang B.H.: Plasma microRNA might asa potential biomarker for hepatocellular carcinoma and chronic liverdisease screening. Tumour Biol., 2015; 36: 7167–7174
  Google Scholar
• 40. Jung E.J., Santarpia L., Kim J., Esteva F.J., Moretti E., Buzdar A.U.,Di Leo A., Le X.F., Bast R.C., Jr., Park S.T., Pusztai L., Calin G.A.: PlasmamicroRNA 210 levels correlate with sensitivity to trastuzumab andtumor presence in breast cancer patients. Cancer, 2012; 118: 2603–2614
  Google Scholar
• 41. Kim J.O., Gazala S., Razzak R., Guo L., Ghosh S., Roa W.H., BédardE.L.: Non-small cell lung cancer detection using microRNA expressionprofiling of bronchoalveolar lavage fluid and sputum. Anticancer Res.,2015; 35: 1873–1880
  Google Scholar
• 42. Kim S.Y., Jeon T.Y., Choi C.I., Kim D.H., Kim D.H., Kim G.H., RyuD.Y., Lee B.E., Kim H.H.: Validation of circulating miRNA biomarkersfor predicting lymph node metastasis in gastric cancer. J. Mol. Diagn,2013; 15: 661–669
  Google Scholar
• 43. Kodahl A.R., Lyng M.B., Binder H., Cold S., Gravgaard K., KnoopA.S., Ditzel H.J.: Novel circulating microRNA signature as a potentialnon-invasive multi-marker test in ER-positive early-stage breast cancer:A case control study. Mol. Oncol., 2014; 8: 874–883
  Google Scholar
• 44. Koga Y., Yamazaki N., Yamamoto Y., Yamamoto S., Saito N.,Kakugawa Y., Otake Y., Matsumoto M., Matsumura Y.: Fecal miR-106a is a useful marker for colorectal cancer patients with falsenegativeresults in immunochemical fecal occult blood test. CancerEpidemiol. Biomarkers Prev., 2013; 22: 1844–1852
  Google Scholar
• 45. Kogo R., Mimori K., Tanaka F., Komune S., Mori M.: Clinicalsignificance of miR-146a in gastric cancer cases. Clin. Cancer Res.,2011; 17: 4277–4284
  Google Scholar
• 46. Kumar S., Keerthana R., Pazhanimuthu A., Perumal P.: Overexpressionof circulating miRNA-21 and miRNA-146a in plasmasamples of breast cancer patients. Indian J. Biochem. Biophys.,2013; 50: 210–214
  Google Scholar
• 47. Larrea E., Sole C., Manterola L., Goicoechea I., Armesto M., ArestinM., Caffarel M.M., Araujo A.M., Araiz M., Fernandez-MercadoM., Lawrie C.H.: New concepts in cancer biomarkers: CirculatingmiRNAs in liquid biopsies. Int. J. Mol. Sci, 2016; 17: 627
  Google Scholar
• 48. Le H.B., Zhu W.Y., Chen D.D., He J.Y., Huang Y.Y., Liu X.G., ZhangY.K.: Evaluation of dynamic change of serum miR-21 and miR-24in pre- and post-operative lung carcinoma patients. Med. Oncol.,2012; 29: 3190–3197
  Google Scholar
• 49. Li J., Liu Y., Wang C., Deng T., Liang H., Wang Y., Huang D., FanQ., Wang X., Ning T., Liu R., Zhang C.Y., Zen K., Chen X., Ba Y.: SerummiRNA expression profile as a prognostic biomarker of stage II/IIIcolorectal adenocarcinoma. Sci. Rep., 2015; 5: 12921
  Google Scholar
• 50. Li X.X., Gao S.Y., Wang P.Y., Zhou X., Li Y.J., Yu Y., Yan Y.F., ZhangH.H., Lv C.J., Zhou H.H., Xie S.Y.: Reduced expression levels of let-7cin human breast cancer patients. Oncol. Lett., 2015; 9: 1207–1212
  Google Scholar
• 51. Lin Q., Chen T., Lin Q., Lin G., Lin J., Chen G., Guo L.: SerummiR-19a expression correlates with worse prognosis of patientswith non-small cell lung cancer. J. Surg. Oncol., 2013; 107: 767–771
  Google Scholar
• 52. Liu F., Wang X., Li J., Gu K., Lv L., Zhang S., Che D., Cao J., JinS., Yu Y.: miR-34c-3p functions as a tumour suppressor by inhibitingeIF4E expression in non-small cell lung cancer. Cell Prolif.,2015; 48: 582–592
  Google Scholar
• 53. Liu J., Mao Q., Liu Y., Hao X., Zhang S., Zhang J.: Analysis ofmiR-205 and miR-155 expression in the blood of breast cancer patients.Chin. J. Cancer Res., 2013; 25: 46–54
  Google Scholar
• 54. Liu W.J., Xu Q., Sun L.P., Dong Q.G., He C.Y., Yuan Y.: Expressionof serum let-7c, let-7i, and let-7f microRNA with its target gene,pepsinogen C, in gastric cancer and precancerous disease. TumourBiol., 2015; 36: 3337–3343
  Google Scholar
• 55. Liu X., Feng J., Tang L., Liao L., Xu Q., Zhu S.: The regulation andfunction of miR-21-FOXO3a-miR-34b/c signaling in breast cancer.Int. J. Mol. Sci., 2015; 16: 3148–3162
  Google Scholar
• 56. Liu X.G., Zhu W.Y., Huang Y.Y., Ma L.N., Zhou S.Q., Wang Y.K.,Zeng F., Zhou J.H., Zhang Y.K.: High expression of serum miR-21and tumor miR-200c associated with poor prognosis in patientswith lung cancer. Med. Oncol., 2012; 29: 618–626
  Google Scholar
• 57. Lu J., Zhan Y., Feng J., Luo J., Fan S.: MicroRNAs associatedwith therapy of non-small cell lung cancer. Int. J. Biol. Sci., 2018;14: 390–397
  Google Scholar
• 58. Ma G.J., Gu R.M., Zhu M., Wen X., Li J.T., Zhang Y.Y., Zhang X.M.,Chen S.Q.: Plasma post-operative miR-21 expression in the prognosisof gastric cancers. Asian Pac. J. Cancer Prev., 2013; 14: 7551–7554
  Google Scholar
• 59. Mar-Aguilar F., Mendoza-Ramirez J.A., Malagón-Santiago I.,Espino-Silva P.K., Santuario-Facio S.K., Ruiz-Flores P., Rodriguez-Padilla C., Reséndez-Pérez D.: Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis.Markers, 2013; 34: 163–169
  Google Scholar
• 60. Matamala N., Vargas M.T., Gonzalez-Cámpora R., MiñambresR., Arias J.I., Menéndez P., Andrés-León E., Gómez-López G., YanowskyK., Calvete-Candenas J., Inglada-Pérez L., Martínez-Delgado B.,Benítez J.: Tumor microRNA expression profiling identifies circulatingmicroRNAs for early breast cancer detection. Clin. Chem.,2015; 61: 1098–1106
  Google Scholar
• 61. Matsumura T., Sugimachi K., Iinuma H., Takahashi Y., KurashigeJ., Sawada G., Ueda M., Uchi R., Ueo H., Takano Y., Shinden Y., EguchiH., Yamamoto H., Doki Y., Mori M. i wsp.: Exosomal microRNAin serum is a novel biomarker of recurrence in human colorectalcancer. Br. J. Cancer, 2015; 113: 275–281
  Google Scholar
• 62. Mazzoccoli G., Colangelo T., Panza A., Rubino R., Tiberio C.,Palumbo O., Carella M., Trombetta D., Gentile A., Tavano F., ValvanoM.R., Storlazzi C.T., Macchia G., De Cata A., Bisceglia G. i wsp.:Analysis of clock gene-miRNA correlation networks reveals candidatedrivers in colorectal cancer. Oncotarget, 2016; 7: 45444–45461
  Google Scholar
• 63. Mishra A.K., Yadav P., Mishra A.: A systemic review on staphylococcalscalded skin syndrome (SSSS): A rare and critical diseaseof neonates. Open Microbiol. J., 2016; 10: 150–159
  Google Scholar
• 64. Muhammad N., Bhattacharya S., Steele R., Ray R.B.: AntimiR- 203 suppresses ER-positive breast cancer growth and stemnessby targeting SOCS3. Oncotarget, 2016; 7: 58595–58605
  Google Scholar
• 65. Mullick Chowdhury S., Wang T.Y., Bachawal S., Devulapally R.,Choe J.W., Abou Elkacem L., Yakub B.K., Wang D.S., Tian L., PaulmuruganR., Willmann J.K.: Ultrasound-guided therapeutic modulationof hepatocellular carcinoma using complementary microRNAs.J. Control Release, 2016; 238: 272–280
  Google Scholar
• 66. Napoli C., Lemieux C., Jorgensen R.: Introduction of a chimericchalcone synthase gene into petunia results in reversible co-suppressionof homologous genes in trans. Plant Cell, 1990; 2: 279–289
  Google Scholar
• 67. Ogata-Kawata H., Izumiya M., Kurioka D., Honma Y., YamadaY., Furuta K., Gunji T., Ohta H., Okamoto H., Sonoda H., WatanabeM., Nakagama H., Yokota J., Kohno T., Tsuchiya N.: Circulatingexosomal microRNAs as biomarkers of colon cancer. PLoS One,2014; 9: e92921
  Google Scholar
• 68. Okabe H., Satoh S., Furukawa Y., Kato T., Hasegawa S., NakajimaY., Yamaoka Y., Nakamura Y.: Involvement of PEG10 in humanhepatocellular carcinogenesis through interaction with SIAH1.Cancer Res., 2003; 63: 3043–3048
  Google Scholar
• 69. Peng Y., Zhang X., Ma Q., Yan R., Qin Y., Zhao Y., Cheng Y., YangM., Wang Q., Feng X., Huang Y., Huang W., Zhao Z., Wang L., Wei Y.i wsp.: MiRNA-194 activates the Wnt/β-catenin signaling pathwayin gastric cancer by targeting the negative Wnt regulator, SUFU.Cancer Lett., 2017; 385: 117–127
  Google Scholar
• 70. Price C., Chen J.: MicroRNAs in cancer biology and therapy:Current status and perspectives. Genes Dis., 2014; 1: 53–63
  Google Scholar
• 71. Rani S., Gately K., Crown J., O’Byrne K., O’Driscoll L.: Globalanalysis of serum microRNAs as potential biomarkers for lung adenocarcinoma.Cancer Biol. Ther., 2013; 14: 1104–1112
  Google Scholar
• 72. Roth C., Kasimir-Bauer S., Pantel K., Schwarzenbach H.: Screeningfor circulating nucleic acids and caspase activity in the peripheralblood as potential diagnostic tools in lung cancer. Mol.Oncol., 2011; 5: 281–291
  Google Scholar
• 73. Ru P., Steele R., Hsueh E.C., Ray R.B.: Anti-miR-203 upregulatesSOCS3 expression in breast cancer cells and enhances cisplatinchemosensitivity. Genes Cancer, 2011; 2: 720–727
  Google Scholar
• 74. Salem O., Erdem N., Jung J., Münstermann E., Wörner A., WilhelmH., Wiemann S., Körner C.: The highly expressed 5’isomiR ofhsa-miR-140-3p contributes to the tumor-suppressive effects ofmiR-140 by reducing breast cancer proliferation and migration.BMC Genomics, 2016; 17: 566
  Google Scholar
• 75. Sassen S., Miska E.A., Caldas C.: MicroRNA: Implications forcancer. Virchows Arch., 2008; 452: 1–10
  Google Scholar
• 76. Setoyama T., Ling H., Natsugoe S., Calin G.A.: Non-coding RNAsfor medical practice in oncology. Keio J. Med, 2011; 60: 106–113
  Google Scholar
• 77. Shiotani A., Murao T., Kimura Y., Matsumoto H., Kamada T.,Kusunoki H., Inoue K., Uedo N., Iishi H., Haruma K.: Identificationof serum miRNAs as novel non-invasive biomarkers for detection ofhigh risk for early gastric cancer. Br. J. Cancer, 2013; 109: 2323–2330
  Google Scholar
• 78. Shyu Y.C., Lee T.L., Lu M.J., Chen J.R., Chien R.N., Chen H.Y., LinJ.F., Tsou A.P., Chen Y.H., Hsieh C.W., Huang T.S.: miR-122-mediatedtranslational repression of PEG10 and its suppression in humanhepatocellular carcinoma. J. Transl. Med., 2016; 14: 200
  Google Scholar
• 79. Silva J., García V., Zaballos Á., Provencio M., Lombardía L.,Almonacid L., García J.M., Domínguez G., Peña C., Diaz R., HerreraM., Varela A., Bonilla F.: Vesicle-related microRNAs in plasma ofnonsmall cell lung cancer patients and correlation with survival.Eur. Respir. J., 2011; 37: 617–623
  Google Scholar
• 80. Song X., Xin N., Wang W., Zhao C.: Wnt/β-catenin, an oncogenicpathway targeted by H. pylori in gastric carcinogenesis.Oncotarget, 2015; 6: 35579–35588
  Google Scholar
• 81. Stahlhut Espinosa C.E., Slack F.J.: The role of microRNAs incancer. Yale J. Biol. Med., 2006; 79: 131–140
  Google Scholar
• 82. Sun Y., Wang M., Lin G., Sun S., Li X., Qi J., Li J.: Serum micro-RNA-155 as a potential biomarker to track disease in breast cancer.PLoS One, 2012; 7: e47003
  Google Scholar
• 83. Tagscherer K.E., Fassl A., Sinkovic T., Richter J., Schecher S.,Macher-Goeppinger S., Roth W.: MicroRNA-210 induces apoptosisin colorectal cancer via induction of reactive oxygen. Cancer CellInt., 2016; 16: 42
  Google Scholar
• 84. Telonis A.G., Loher P., Jing Y., Londin E., Rigoutsos I.: Beyondthe one-locus-one-miRNA paradigm: microRNA isoforms enabledeeper insights into breast cancer heterogeneity. Nucleic AcidsRes., 2015; 43: 9158–9175
  Google Scholar
• 85. Teplyuk N.M., Mollenhauer B., Gabriely G., Giese A., Kim E.,Smolsky M., Kim R.Y., Saria M.G., Pastorino S., Kesari S., KrichevskyA.M.: MicroRNAs in cerebrospinal fluid identify glioblastoma andmetastatic brain cancers and reflect disease activity. Neuro. Oncol.,2012; 14: 689–700
  Google Scholar
• 86. Toiyama Y., Takahashi M., Hur K., Nagasaka T., Tanaka K., InoueY., Kusunoki M., Boland C.R., Goel A.: Serum miR-21 as a diagnosticand prognostic biomarker in colorectal cancer. J. Natl. CancerInst., 2013; 105: 849–859
  Google Scholar
• 87. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., JemalA.: Global cancer statistics. 2012. CA Cancer J. Clin., 2015; 65: 87–108
  Google Scholar
• 88. Tsujiura M., Ichikawa D., Komatsu S., Shiozaki A., TakeshitaH., Kosuga T., Konishi H., Morimura R., Deguchi K., Fujiwara H.,Okamoto K., Otsuji E.: Circulating microRNAs in plasma of patientswith gastric cancers. Br. J. Cancer, 2010; 102: 1174–1179
  Google Scholar
• 89. Tsujiura M., Komatsu S., Ichikawa D., Shiozaki A., Konishi H.,Takeshita H., Moriumura R., Nagata H., Kawaguchi T., Hirajima S.,Arita T., Fujiwara H., Okamoto K., Otsuji E.: Circulating miR-18a inplasma contributes to cancer detection and monitoring in patientswith gastric cancer. Gastric Cancer, 2015; 18: 271–279
  Google Scholar
• 90. Wang F., Hou J., Jin W., Li J., Yue Y., Jin H., Wang X.: Increasedcirculating microRNA-155 as a potential biomarker for breast cancerscreening: A meta-analysis. Molecules, 2014; 19: 6282–6293
  Google Scholar
• 91. Wang G., Wang L., Sun S., Wu J., Wang Q.: Quantitative measurementof serum microRNA-21 expression in relation to breast cancermetastasis in Chinese females. Ann. Lab. Med., 2015; 35: 226–232
  Google Scholar
• 92. Wang H., Hou L., Li A., Duan Y., Gao H., Song X.: Expression ofserum exosomal microRNA-21 in human hepatocellular carcinoma.Biomed. Res. Int., 2014; 2014: 864894
  Google Scholar
• 93. Wang H., Wang L., Wu Z., Sun R., Jin H., Ma J., Liu L., Ling R.,Yi J., Wang L., Bian J., Chen J., Li N., Yuan S., Yun J.: Three dysregulatedmicroRNAs in serum as novel biomarkers for gastric cancerscreening. Med. Oncol., 2014; 31: 298
  Google Scholar
• 94. Wang L.G., Gu J.: Serum microRNA-29a is a promising novelmarker for early detection of colorectal liver metastasis. CancerEpidemiol., 2012; 36: e61–e67
  Google Scholar
• 95. Wang R.J., Zheng Y.H., Wang P., Zhang J.Z.: Serum miR-125a-5p,miR-145 and miR-146a as diagnostic biomarkers in non-small celllung cancer. Int. J. Clin. Exp. Pathol., 2015; 8: 765–771
  Google Scholar
• 96. WHO: Cancer Fact Sheets. https://www.who.int/news-room/fact-sheets/detail/cancer (31.10.2018)
  Google Scholar
• 97. Wu C., Cao Y., He Z., He J., Hu C., Duan H., Jiang J.: Serum levelsof miR-19b and miR-146a as prognostic biomarkers for non-smallcell lung cancer. Tohoku J. Exp. Med., 2014; 232: 85–95
  Google Scholar
• 98. Wu H.H., Lin W.C., Tsai K.W.: Advances in molecular biomarkersfor gastric cancer: miRNAs as emerging novel cancer markers.Expert Rev. Mol. Med., 2014; 16: e1
  Google Scholar
• 99. Wu J., Li G., Wang Z., Yao Y., Chen R., Pu X.Y., Wang J.: CirculatingmicroRNA-21 is a potential diagnostic biomarker in gastriccancer. Dis. Markers, 2015; 2015: 435656
  Google Scholar
• 100. Wu Q., Lu Z., Li H., Lu J., Guo L., Ge Q.: Next-generation sequencingof microRNAs for breast cancer detection. J. Biomed.Biotechnol., 2011; 2011: 597145
  Google Scholar
• 101. Wu Q., Wang C., Lu Z., Guo L., Ge Q.: Analysis of serum genome-wide microRNAs for breast cancer detection. Clin. Chim.Acta, 2012; 413: 1058–1065
  Google Scholar
• 102. Wu X., Somlo G., Yu Y., Palomares M.R., Li A.X., Zhou W.,Chow A., Yen Y., Rossi J.J., Gao H., Wang J., Yuan Y.C., Frankel P., LiS., Ashing-Giwa K.T. i wsp.: De novo sequencing of circulating miRNAsidentifies novel markers predicting clinical outcome of locallyadvanced breast cancer. J. Transl. Med., 2012; 10: 42
  Google Scholar
• 103. Xiao B., Zhu E.D., Li N., Lu D.S., Li W., Li B.S., Zhao Y.L., MaoX.H., Guo G., Yu P.W., Zou Q.M.: Increased miR-146a in gastric cancerdirectly targets SMAD4 and is involved in modulating cell proliferationand apoptosis. Oncol. Rep., 2012; 27: 559–566
  Google Scholar
• 104. Xu L., Li M., Wang M., Yan D., Feng G., An G.: The expressionof microRNA-375 in plasma and tissue is matched in human colorectalcancer. BMC Cancer, 2014; 14: 714
  Google Scholar
• 105. Yang I.P., Tsai H.L., Huang C.W., Huang M.Y., Hou M.F., JuoS.H., Wang J.Y.: The functional significance of microRNA-29c inpatients with colorectal cancer: A potential circulating biomarkerfor predicting early relapse. PLoS One, 2013; 8: e66842
  Google Scholar
• 106. Yang J.S., Li B.J., Lu H.W., Chen Y., Lu C., Zhu R.X., Liu S.H.,Yi Q.T., Li J., Song C.H.: Serum miR-152, miR-148a, miR-148b, andmiR-21 as novel biomarkers in non-small cell lung cancer screening.Tumour Biol., 2015; 36: 3035–3042
  Google Scholar
• 107. Yau T.O., Wu C.W., Dong Y., Tang C.M., Ng S.S., Chan F.K., SungJ.J., Yu J.: microRNA-221 and microRNA-18a identification in stoolas potential biomarkers for the non-invasive diagnosis of colorectalcarcinoma. Br. J. Cancer, 2014; 111: 1765–1771
  Google Scholar
• 108. Yau T.O., Wu C.W., Tang C.M., Chen Y., Fang J., Dong Y., LiangQ., Ng S.S., Chan F.K., Sung J.J., Yu J.: MicroRNA-20a in human faecesas a non-invasive biomarker for colorectal cancer. Oncotarget,2016; 7: 1559–1568
  Google Scholar
• 109. Yin J., Bai Z., Song J., Yang Y., Wang J., Han W., Zhang J., MengH., Ma X., Yang Y., Wang T., Li W., Zhang Z.: Differential expressionof serum miR-126, miR-141 and miR-21 as novel biomarkersfor early detection of liver metastasis in colorectal cancer. Chin.J. Cancer Res., 2014; 26: 95–103
  Google Scholar
• 110. Yu H., Jiang L., Sun C., Li Guo L., Lin M., Huang J., Zhu L.: Decreasedcirculating miR-375: A potential biomarker for patientswith non-small-cell lung cancer. Gene, 2014; 534: 60–65
  Google Scholar
• 111. Yuan R., Wang G., Xu Z., Zhao H., Chen H., Han Y., Wang B.,Zhou J., Hu H., Guo Z., Shen H., Xue X.: Up-regulated circulatingmiR-106a by DNA methylation promised a potential diagnosticand prognostic marker for gastric cancer. Anticancer Agents Med.Chem., 2016; 16: 1093–1100
  Google Scholar
• 112. Yuxia M., Zhennan T., Wei Z.: Circulating miR-125b is a novelbiomarker for screening non-small-cell lung cancer and predictspoor prognosis. J. Cancer Res. Clin. Oncol., 2012; 138: 2045–2050
  Google Scholar
• 113. Zang H., Wang W., Fan S.: The role of microRNAs in resistanceto targeted treatments of non-small cell lung cancer. CancerChemother, Pharmacol., 2017; 79: 227–231
  Google Scholar
• 114. Zeng Q., Jin C., Chen W., Xia F., Wang Q., Fan F., Du J., Guo Y.,Lin C., Yang K., Li J., Peng X., Li X., Cao K.: Downregulation of serummiR-17 and miR-106b levels in gastric cancer and benign gastricdiseases. Chin. J. Cancer Res., 2014; 26: 711–716
  Google Scholar
• 115. Zhang J., Song Y., Zhang C., Zhi X., Fu H., Ma Y., Chen Y., PanF., Wang K., Ni J., Jin W., He X., Su H., Cui D.: Circulating MiR-16-5pand MiR-19b-3p as two novel potential biomarkers to indicate progressionof gastric cancer. Theranostics, 2015; 5: 733–745
  Google Scholar
• 116. Zhang R., Wang W., Li F., Zhang H., Liu J.: MicroRNA-106b~25expressions in tumor tissues and plasma of patients with gastriccancers. Med. Oncol., 2014; 31: 243
  Google Scholar
• 117. Zhao W., Zhao J.J., Zhang L., Xu Q.F., Zhao Y.M., Shi X.Y., XuA.G.: Serum miR-21 level: A potential diagnostic and prognosticbiomarker for non-small cell lung cancer. Int. J. Clin. Exp. Med.,2015; 8: 14759–14763
  Google Scholar
• 118. Zheng R., Pan L., Gao J., Ye X., Chen L., Zhang X., Tang W.,Zheng W.: Prognostic value of miR-106b expression in breast cancerpatients. J. Surg. Res., 2015; 195: 158–165
  Google Scholar
• 119. Zhu W., He J., Chen D., Zhang B., Xu L., Ma H., Liu X., ZhangY., Le H.: Expression of miR-29c, miR-93, and miR-429 as potentialbiomarkers for detection of early stage non-small lung cancer.PLoS One, 2014; 9: e87780
  Google Scholar
• 120. Zhuang C., Jiang W., Huang D., Xu L., Yang Q., Zheng L., WangX., Hu L.: Serum miR-21, miR-26a and miR-101 as potential biomarkersof hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol.,2016; 40: 386–396
  Google Scholar

Pełna treść artykułu